Mercer Louise, Abhishek Abhishek, Kavirayani Akhila, Ahmed Alison, Davidson Alan, Foulkes Amy, Jones Claire, Nash Clare, Rose-Parfitt Emily, Dhillon Emmandeep, Zabate Genevieve, Twohig Helen, De Vere Hope, Scott Jennifer, Reynolds John, Holmes Julia, Hartley Karen, Warrier Kishore, Nowak Kataryzna, Parsons Kate, Bechman Katie, Bray Lisa, Adikari Madura, Wood Natasha, Faithfull Nicola, Gullick Nicola, Saha Pratyasha, Heaton Rebecca, Deepak Samundeeswari, Hider Samantha, Khalid Sameena, Said Sanaa Suleiman, Ryan Sarah, Kyle Stuart, Raghuvanshi Subhra, Tan Su-Yin, Shivamurthy Vinay, Galloway James
Department of Rheumatology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK.
Academic Rheumatology, City Hospital Nottingham, University of Nottingham, Nottingham, UK.
Rheumatol Adv Pract. 2024 Jul 12;8(3):rkae077. doi: 10.1093/rap/rkae077. eCollection 2024.
This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.
本指南将针对非生物改善病情抗风湿药（也称为传统合成改善病情抗风湿药，即csDMARD）在全谱系自身免疫性风湿疾病中的安全使用提供最新的、循证的建议。该指南将更新2017年发布的指南，并将扩大范围以涵盖所有年龄段的人群。其中将纳入有关改善病情抗风湿药监测及疫苗接种的最新信息。本指南将采用英国风湿病学会2023年更新的《制定临床指南：我们的方案》中所描述的方法和流程来制定。
